Skip to main content

Table 1 Demographic data and characteristic findings in patients with retinopathy of prematurity received intravitreal Bevacizumab (IVB) vs. intravitreal Aflibercept (IVA)

From: Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

Parameter Level Total Type of Treatment p
IVB IVA
GA (weeks) Mean ± SD 28.2 ± 2 28.2 ± 2 28.7 ± 2.3 0.230†
Median (range) 28 (22 to 34) 28 (22 to 34) 28.5 (25 to 34)
BW (g) Mean ± SD 1121 ± 314 1119 ± 311 1205 ± 383 0.182†
Median (range) 1060 (550 to 2700) 1050 (550 to 2700) 1190 (730 to 1975)
Time of first treatment Mean ± SD 59 ± 19 59 ± 19 55 ± 21 0.536¥
Median 57 57 49
Follow up (days) Mean ± SD 285 ± 255 289 ± 257 143 ± 25  < 0.001¥
Median 212 217 137
Gender Male 260 252 (57.2%) 8 (66.7%) 0.362*
  Female 193 189 (42.8%) 4 (33.3%)  
Twin Yes 108 107 (24.3%) 1 (8.3%) 0.099*
  No 345 334 (75.7%) 11 (91.7%)  
O2 therapy Yes 400 390 (88.4%) 10 (83.3%) 0.054**
  No 53 51 (11.6%) 2 (16.7%)  
Intubation Yes 178 176 (40%) 2 (16.7%) 0.130*
  No 275 265 (60%) 10 (83.3%)  
Transfusion Yes 257 247 (56%) 10 (83.3%) 0.077*
  No 196 194 (44%) 2 (16.7%)  
Intraventricular Hemorrhage Yes 33 31 (7%) 2 (16.7%) 0.096**
  No 420 410 (93%) 10 (83.3%)  
Sepsis Yes 177 173 (39.2%) 4 (33.3%) 0.673*
  No 276 268 (60.8%) 8 (66.7%)  
Phototherapy Yes 297 293 (66.4%) 4 (33.3%)  < 0.001*
  No 156 148 (33.6%) 8 (66.7%)  
Anemia Yes 46 39 (8.8%) 7 (58.3%)  < 0.001**
  No 407 402 (91.2%) 5 (41.7%)  
Acute respiratory distress syndrome Yes 230 230 (52.2%) 0  < 0.001*
  No 223 21 1(47.8%) 12(100%)  
Laterality Unilateral 17 (3.8%) 17 (3.9%) 0 (0.0%)  > 0.99**
Bilateral 436 (96.2%) 424 (96.1%) 12 (100.0%)
Eye OD 443 (49.8%) 431 (49.8%) 12 (50.0%) 0.476¥
OS 446 (50.2%) 434 (50.2%) 12 (50.0%)
Zone pretreatment 1 197 (22.2%) 187 (21.6%) 10 (41.7%) 0.328¥
2 692 (77.8%) 678 (78.4%) 14 (58.3%)
Plus Yes 885 (99.6%) 861 (99.5%) 24 (100.0%) 0.734¥
No 4 (0.4%) 4 (0.5%) 0 (0.0%)
Neovascularization of iris Yes 58 (6.5%) 54 (6.2%) 4 (16.7%) 0.331¥
No 831 (93.5%) 811 (93.8%) 20 (83.3%)
  1. † Based on t-test
  2. * Based on Chi-Square test
  3. ** Based on Fisher exact test
  4. ¥ Based on GEE